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ABSTRACT
The treatment of benign bone tumors (BBT) and tumor-
like bone lesions (TBL) has observed the introduction of 
new drugs, such as intravenous bisphosphonates, which 
have ossified bone lesions caused by fibrous dysplasia. 
Aneurismal bone cyst has been treated with sclerosing 
agents by percutaneous injection, yielding good results. 
Adjuvants allow joint salvage, maintenance of movements 
and function, with low rates of recurrence. Among them, 
the most used ones are bone cement (PMMA), phenol, 
nitrogen-based cryotherapy, hydrogen peroxide, ethanol 
and radiotherapy. New methods of treatment include 
thermal ablation with radiofrequency and laser, mainly 
utilized for treating osteoid osteoma. Arthroscopy allows 
resection of benign intra-joint lesions and assists the 
surgery of subchondral tumors. A great advance is the 
utilization of synthetic bone substitutes, which are a mixture 
of osteoinductive growth factors and osteoconductive 
ceramics, and have presented comparable results to 
autogenous bone grafts. There is a recent trend for closed 
treatments, with percutaneous injection of demineralized 
bone matrix (DBM) and calcium sulfate. Autogenous 
cancellous bone graft remains as the gold standard. 
Vascularized fibula graft, on the other hand, incorporates 
faster in the treatment of large destructive lesions. Also, 
allogenic cortical support allows structural augmentation 
for aggressive tumors. Freeze-dried allografts are used to 
fill contained defects and as expanders of autografts. Joint 
endoprosthesis may be used in large destructive lesions of 
the distal femur, hip and shoulder. 
Keywords – Bone diseases; Bone neoplasms/surgery; Bone 
neoplasms /therapy; Bone neoplasms /chemotherapy; Bone 
neoplasms/radiotherapy
INTRODUCTION
Benign primary bone tumors are relatively rare, 
which creates some difficulty for diagnosis and 
treatment. Tumor-like bone lesions are non-neo-
plastic lesions that simulate tumors. An awareness 
of them is important since they can be confused 
with bone tumors and receive excessive or inad-
equate treatment. 
Benign bone tumors and tumor-like bone lesions 
occur most frequently between the ages of five to 
25 years and in the areas of greatest bone growth, 
with about 60% of cases in the knee region. For this 
reason, they can cause osteoarticular deformities, 
fractures, limb length discrepancies, gait distur-
bances, sometimes with disabling sequelae.
Treatment of these lesions has undergone recent 
and ongoing innovations such as the use of new 
drugs, new types of adjuvants, synthetic bone graft 
substitutes, and advanced arthroscopy and radio 
frequency techniques.
The objective of this study was to describe the 
most current and emerging trends in the treatment 
of benign bone tumors (BBT) and tumor-like bone 
lesions (TLBL).
Rev Bras Ortop. 2009;44(5):386-90
© 2009 Sociedade Brasileira de Ortopedia e Traumatologia. Open access under CC BY-NC-ND license.
387
TREATMENT
Medications
Some benign tumors can be treated with different 
types of medications. The knowledge and treatment 
of fibrous dysplasia have evolved much over the 
past ten years. Frequent recurrences after their 
traditional treatment of curettage and bone grafting 
are explained by what is now known about its genetic 
nature. Recently, the disease has been treated with 
intravenous bisphosphonate that inhibits the bone 
resorption mediated by osteoclasts. Initial results 
in fibrous dysplasia have shown a decrease in pain, 
the prevention of fractures, and partial radiographic 
resolution of lesions. Pamidronate is the most 
commonly used third-generation bisphosphonate 
and is administered by monthly intravenous infusion 
over a period of two to four hours. It has also 
been used in Paget’s disease and metastatic bone 
disease with good results. Zoledronic acid and other 
bisphosphonates have anti-tumor activity and can 
reduce the bone tumor burden, prevent metastasis 
and inhibit the progression of bone lesions(1).
For the treatment of simple bone cysts, methyl-
prednisolone acetate is the most commonly used 
medication for infiltration, with good results(1).
The use of fibrosing agents for the treatment of 
aneurysmal bone cyst (ABC) presents controver-
sial results. Treatment with zein-alcohol solution 
showed high rates of local and systemic compli-
cations and has been abandoned(2). Sclerotherapy 
with polidocanol was safer and more effective, with 
published long follow-up results(3).
Adjuvants
The use of adjuvants aims to eradicate micro-
scopic disease by thermal and chemical means. The 
current trend is the preservation of the joint with 
intralesional surgery and use of adjuvants in the 
treatment of benign bone lesions(4,5). Wide excision 
has lower recurrence rates but worse functional 
outcomes.
Treatment of giant cell tumor (GCT) with 
intralesional excision, cauterization and the use of 
phenol over bone cement (polymethylmethacrylate, 
PMMA) as an adjuvant has shown excellent 
functional results and low rates of relapse and 
secondary osteoarthritis(4).
Bone cement provides immediate structural sta-
bility, but there is no evidence of a tumoricidal 
effect from thermal necrosis of tumor cells. Phenol 
is a non-selective cytotoxic agent that acts on other 
tissues and is systemically toxic. It is used locally 
in the cavity and produces superficial cell death 
over 1 to 2mm(6).
Cryotherapy with liquid nitrogen is curative 
treatment for benign aggressive and low-grade ma-
lignant bone tumors(7). It is also useful for the local 
control and symptomatic relief of metastatic bone 
disease. Bone necrosis produced from the cavity 
makes cryosurgery, which is intralesional by defi-
nition, as effective as a wide excision. The surgi-
cal technique consists of exposure, curettage and 
margin expansion with a rotary drill, cryosurgery, 
bone cement reconstruction, internal fixation, and 
subchondral bone graft. Osteosynthesis and pro-
tection from impact for six months are important 
in preventing a pathological fracture because bone 
regeneration occurs slowly(7).
Cryosurgery can produce cell necrosis up to 2 
cm from the bone surface and, in this respect, is 
more effective than cement and phenol. To reduce 
the complication rate of cryosurgery with direct in-
stillation of liquid nitrogen in an open system, new 
techniques were developed to allow for the control 
of temperature and freezing time and so that the 
whole cavity, independent of geometric shape and 
irregularities, is evenly treated. Pressurized liquid 
nitrogen and argon gas spray is used(6,8).
Hydrogen peroxide (H2O2) is used clinically 
as a chemical adjuvant to the removal of residual 
tumor cells in intralesional curettage surgery for 
GCT. It causes the lysis and death of tumor cells 
and has shown low rates of recurrence when asso-
ciated with bone cement(9). Ethyl alcohol has been 
used in osteoid osteoma by injection into the nidus 
guided by computed tomography (CT) (5,10).
Radiation therapy is very effective in stopping 
the progression of or achieving full and permanent 
resolution of benign mesenchymal diseases, but 
there is a small risk of malignant lesion(11). It pro-
vides good results in hemangioma of the vertebral 
body and the sacrum. In GCT and ABC, it may be 
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indicated for lesions that are difficult to access, 
recurrences in the spine and pelvis, or for patients 
that are medically unfit for surgery. In primary or 
metastatic tumors of the sacrum, radiotherapy alone 
or combined with surgery and radiosurgery are in-
dicated(12).
Radiofrequency
Radiofrequency ablation uses long wave electro-
magnetic radiation to produce thermal coagulation.
A comparative study between CT-guided per-
cutaneous ablation and open surgical treatment 
for osteoid osteoma suggests that the methods are 
essentially equivalent(13). The percutaneous radio-
frequency method is preferred because it does not 
require hospitalization, is not associated with com-
plications, and allows rapid recovery. It is indi-
cated for lesions that are not closely adjacent to 
the neurovascular structures in the appendicular 
skeleton and pelvis. It is contraindicated in the hand 
and spine. Needle biopsy is performed during the 
same surgery. Two large series of patients treated at 
the Massachusetts General Hospital (MGH) and the 
Istituti Ortopedici Rizzoli have been published(14,15).
The technique has more recently been used for 
the treatment of chondroblastoma(16), pain in bone 
metastases, and recurrence of chordoma(15).
Thermal laser therapy guided by CT has also been 
successful. The laser energy transmitted by the fiber 
optic cable produces heat and cell necrosis(5,15).
Arthroscopy
Arthroscopic biopsy and surgical treatment are 
recommended for selected intra-articular lesions, 
such as pigmented villonodular synovitis, synovial 
chondromatosis, arborescent lipoma, synovial an-
gioma, intra-articular synovial lipoma, and osteo-
chondroma(17-19).
Even minimally invasive procedures such as ar-
throscopy may have adverse consequences in the 
presence of an unsuspected neoplasia. Before ar-
throscopy, non-invasive tests should be performed, 
including magnetic resonance imaging when indi-
cated, to rule out tumor. Unwarranted arthroscopy 
can contaminate the joint, hamper limb salvage sur-
gery, and even lead to amputation(17).
Additionally, arthroscopy is a useful adjunct 
during open surgical treatment of patients with 
certain juxta-articular benign bone tumors such 
as GCT and chondroblastoma. Arthroscopic 
curettage has technical limitations and there are 
limitations in the tumor biology, and is not the 
standard procedure thus far. Curettage should be 
made through the cortical bone window with the 
assistance of arthroscopy to visualize the joint 
surfaces and observe joint integrity while pursuing 
open subchondral curettage and filling with graft or 
cement without damaging the articular cartilage(17,20).
Juxta-articular osteoid osteoma at the knee and 
the hip, involving the acetabulum and the femoral 
neck, can be resected with the aid of arthroscopy 
and CT, with minimal morbidity, excellent relief 
of symptoms, and rapid functional recovery(20,21).
Arthroscopy has been performed for resection 
of intra- and periarticular exostoses in the hip and 
knee that were causing pain, restrictions of move-
ment, subluxation, and early joint damage. The risk 
of iatrogenic injury and necrosis of the femoral 
head is smaller because there is no need for hip 
dislocation to access the exostosis(18,19).
Endoscopic curettage without bone grafting can 
be used in cases of extra-articular benign bone tu-
mors without extension into soft tissues. The tumor 
cavity is large enough for endoscopy(22).
Synthetic bone substitutes
The ideal synthetic bone graft should provide 
osteoinductive growth, undifferentiated primitive 
mesenchymal cells (stem cells), osteoconductive 
material to create a structural framework, a 
favorable environment for good cell function 
and the formation of new bone with complete 
integration into the host(23, 24).
Demineralized bone matrix (DBM)(25), bone 
morphogenetic protein (BMP), and growth factors 
(fibroblast, platelet, insulin and other) are osteoin-
ductive(23). Injections of autologous bone marrow 
with multipotent stem cells promote osteogenesis.
Calcium phosphate is the primary ceramic that is 
osteoconductive to reconstruction, as are hydroxy-
apatite (HA), tricalcium phosphate (TCP), the com-
bination of these two (HA-TCP)(26,27), and calcium 
sulfate (gypsum)(23,24,28,29).
Composite grafts are made of materials that 
include a combined osteoconductive matrix,with 
osteogenic cells, or with osteoinductive growth 
factors(23,24,28,29,30). They are widely used in 
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craniofacial reconstruction, benign bone tumors, 
as bone graft expanders or graft substitutes in 
stabilized fractures and nonunions. Their results are 
comparable to autogenous bone graft and without 
morbidity. They are certain to surpass the well-
established autogenous “gold standard”(23,30).
There is currently a trend towards closed, 
minimally invasive treatment of benign lesions 
such as non-ossifying fibroma, aneurysmal and 
simple bone cysts, with percutaneous injection 
without open curettage with demineralized bone 
matrix (DBM) associated with calcium sulfate(30) 
or bone marrow aspirate from the iliac crest, 
which provides stem cells(1,31). Injectable calcium 
phosphate and hydroxyapatite have been used 
in fractures and benign tumors, functioning as 
cement and creating mechanical strength(24).
Bone grafts
The autogenous cancellous bone graft is 
considered the gold standard. It has the basic 
components for integration and healing: 
osteoinductive growth factors, an osteoconductive 
matrix, osteogenic stem cells from bone marrow(23). 
The disadvantages would be surgical morbidity at 
the donor site and few donor sites in the skeletal 
system, with a limited amount of graft.
 !"#$%!&'()*+ ,-$%!&+ .&!/0"+ !&)+ '1#2&32&!0)*+42&)+
rapidly than non-vascularized grafts and show 
superior results in the treatment of aggressive 
benign bone tumors(32).
Surgery with osteochondral autograft transfer 
can be performed to treat benign tumors juxtaposed 
to articular cartilage and with erosion of the same. 
The graft is usually removed from the lateral 
condyle of the femur(33).
The allograft is less desirable for its risk 
of immune rejection, potential for disease 
transmission, infection, and its inferiority in 
incorporating biologically. It has osteoconductive 
properties, but limited osteoinductive potential(23). 
Demineralization increases its biological 
performance and better processing reduces the 
risk of transmitting infection. Frozen allograft is 
more often used for osteoarticular reconstruction 
in large resections, and lyophilized allografts 
to fill contained defects, and for enhancing the 
autogenous bone graft(24).
In the treatment of BBT and TLBL with large 
bone defects, the reconstructive technique that uses 
allogeneic cortical support provides for increased 
resistance, easy fixation, cystic defect remodeling, 
fracture healing, and prevention of deformity. However, 
remodeling occurs slowly and may not be complete. 
It may be associated with adjuvants such as alcohol 
and phenol, allogeneic cancellous bone graft and 
osteosynthesis, if necessary (usually in the femur)(34).
Embolization
Selective arterial embolization may be used 
preoperatively as an adjuvant to reduce surgical 
bleeding, or as a definitive single treatment when 
surgery is contraindicated(1,31,35).
Although surgery is the main treatment for many 
benign, malignant, and metastatic sacral tumors, 
embolization is a valuable primary or adjuvant 
therapy. Patients with benign lesions, including ABC 
and GCT, respond to embolization with resolution of 
symptoms and ossification of the lesions(36).
Surgery
Distal femoral resection and reconstruction with an 
unconventional endoprosthesis is a safe and reliable 
technique that provides good function and local tumor 
control in most patients. Gastrocnemius muscle flaps are 
used in the reconstruction of soft tissue. It is indicated 
for malignant and benign aggressive tumors such as the 
GCT and the rate of limb salvage reaches 96%(37).
Endoprostheses are also useful in the 
reconstruction of large defects in the proximal femur 
and humerus. Other techniques that may be used for 
joint reconstruction are alloprosthetic composites 
and solid osteoarticular allografts associated with 
osteosynthesis(24). Autogenous or allogeneic bone 
grafting is also indicated when performing arthrodesis.
The most common treatment for aneurysmal bone 
cyst and other benign tumors such as chondroblas-
toma, enchondroma, osteoblastoma, and chondro-
myxoid fibroma is marginal extracapsular excision 
using a high-speed drill and filling the cavity with 
autogenous bone graft or allograft. Adjuvants such as 
phenol, liquid nitrogen, and bone cement can be used 
in aggressive and recurrent lesions, reducing recur-
rence rates(1,5,31,35). Wide excision has a lower risk of 
relapse and may be more appropriate in expendable 
bones and eccentric lesions in long bones.
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